<div><div></div><div><span><p><strong><span>Wave Life Sciences reported positive RestorAATion-2 results showing WVE-006 restores protective M-AAT and markedly reduces harmful Z-AAT.</span></strong></p><p><strong><span>Key Highlights:</span></strong></p><ul><li><span>WVE-006 generated wild-type M-AAT at 64% of total and reduced Z-AAT by 71% in the 200 mg biweekly multidose cohort.</span></li><li><span>400 mg monthly multidose produced similar effects: 58.7% M-AAT and 13.6 µM total AAT, supporting monthly dosing.</span></li><li><span>Single-dose reductions in Z-AAT were dose-dependent: 47.3% (200 mg), 49.7% (400 mg), 59.1% (600 mg).</span></li><li><span>RNA editing effects were durable (sustained ≥3 months post-dose) and WVE-006 was generally well tolerated with no liver toxicities.</span></li><li><span>Wave expects FDA feedback on a potential accelerated approval pathway mid-2026 and will share 600 mg multidose data in H2 2026.</span></li></ul><p><span>Original SEC Filing: </span>Wave Life Sciences Ltd. [ WVE ] - 8-K - May. 18, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

ARKG

SBIO

LABU

<p>Wave Life Sciences announced positive results from the RestorAATion-2 trial, showing that WVE-006 effectively restores M-AAT levels and reduces Z-AAT levels. In the 200 mg biweekly cohort, M-AAT reached 64% of total, while Z-AAT decreased by 71%. The 400 mg monthly dosing also showed significant results. The treatment was well tolerated with no liver toxicities. The company anticipates FDA feedback on accelerated approval by mid-2026 and plans to present further data in H2 2026.</p>

TradingView

Wave Life Sciences

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Bioshares Biotech Clinical Trials Fd

SPDR S&P Biotech

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing